Intracorporeal Vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy

Not Applicable

Completed

• Conditions: Bladder Cancer
• Interventions: Procedure: Extracorporeal Urinary Diversion; Procedure: Intracorporal Urinary Diversion; Device: Da Vinci Robot

• Registration Number: NCT03469362
• Lead Sponsor: University of Miami

Brief Summary

Intracorporeal urinary diversion (ICD) provides superior postoperative outcomes compared to extracorporeal urinary diversion (ECD). The investigators' hypothesis that ICD may provide clinical benefit is based on principles of less bowel and ureteral handling, superior operating room workflow, less exposure to the external environment, and optimal visualization with ICD while utilizing a smaller incision compared to ECD. ICD should have less bowel-related complications, lower pain scores allowing patients to be discharged from the hospital sooner and regain functional independence more quickly.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2018-03-06
• Study First Submitted QC: 2018-03-12
• Study First Posted: 2018-03-19
• Study Start: 2018-04-25
• Primary Completion: 2024-08-20
• Study Completion: 2024-09-11
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-20
• Last Update Posted: 2024-11-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 38

Inclusion Criteria

• Biopsy-proven urothelial cancer being considered for RARC.
• Clinical stage T1-T4, N0-1, M0 or refractory carcinoma in situ.
• Subject must be already scheduled to have a RARC at the discretion of the surgeon and with the patient's agreement.

Read More

Exclusion Criteria

• Inability to give informed consent
• Prior major abdominal and pelvic open surgical procedures that would preclude a safe robotic approach, as determined by the treating surgeon.
• At the discretion of the treating surgeon, any pre-existing condition such as severe chronic obstructive pulmonary disease that precludes a safe initiation or maintenance of pneumoperitoneum over a prolonged period of time and during surgery.
• Age <18 or >99 years.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Extracorporeal Urinary Diversion (ECD)	Extracorporeal Urinary Diversion	Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
Intracorporal Urinary Diversion (ICD)	Intracorporal Urinary Diversion	Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
Intracorporal Urinary Diversion (ICD)	Da Vinci Robot	Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).

Primary Outcome Measures

Name	Time	Method
90-day Major Post-Operative Complication Rate	90 days	Major complication rate at 90-days from RARC + urinary diversion using the modified Clavien-Dindo grading system. Major complication is defined as Clavien-Dindo Grade ≥ 3.

Secondary Outcome Measures

Name	Time	Method
Length of Hospital Stay in ECD vs ICD Study Participants	About 2 weeks	Length of hospital stay for study participants undergoing ECD versus ICD urinary diversion post-RARC, as recorded at hospital discharge.
Mortality Rate at 90 days	90 days	Rate of mortality (death) at 90 days in study participants
Functional Independence Recovery as measured by the Hand Grip Strength Test.	Up to 36 months	The Hand Grip Strength Test measures the amount of static force that a participant's hand can squeeze around a dynamometer. The test is measured in kilograms.
Functional Independence Recovery as measured by the Timed Up and Go (TUG) Walking Test	Up to 36 months	The TUG test times participants as they rise from a standard chair, walk 3 meters, turn, walk back and sit again. The test is measured in seconds.
90-day Readmission Rate	90 days	Rate of readmission to hospital at 90 days post-RARC followed by ECD or ICD urinary diversion.
90-day Any Post-Operative Complication Rate	90 days	Any complication rates at 90-days from RARC + urinary diversion, using the modified Clavien-Dindo grading system as low grade (1-2) or high grade (3-5).
Rate of Return to the Operating room within 90 days	Up to 90 days	Rate of return to the operating room within 90 days after RARC followed by ICD or ECD Urinary Diversion.
Functional Independence Recovery as measured by the ADL Questionnaire	Up to 36 months	Rate of functional independence recovery as measured by patient-reported scores on the Activities of Daily Living (ADL) questionnaire. For the ADL, the total score ranges from 0 to 6, with the higher scores indicating functional improvement and lower scores indicating functional deterioration.
Functional Independence Recovery as measured by the IADL Questionnaire	Up to 36 months	Rate of functional independence recovery as measured by an aggregate of patient-reported scores on the Instrumental Activities of Daily Living (IADL) questionnaire. For the IADL, the total score ranges from 0 to 8, with higher scores indicating functional functional improvement and lower scores indicating functional deterioration.
Health-Related Quality of Life (HRQoL) as assessed by SF-8 Health Survey	Up to 36 months	HRQoL measured by patient scores on the Short Form 8 (SF-8) Health Survey. The SF-8 is a questionnaire consisting of 8-items and two component summary scores: Physical component summary (PCS) and mental component summary (MCS). They are scored by weighting each score to a norm-based scoring model. The total scores will be reported as a percentile with higher score indicating better health-related quality of life.
Rate of Bowel-Specific Complications	Up to 36 months	Rate of bowel-specific complications in study participants (including incidence of mechanical bowel obstruction, anastomotic leaks, and surgical site infections) and post operative pain. Bowel-specific complications will be assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.
HRQoL as assessed by the FACT-VCI Questionnaire	Up to 36 months	HRQoL measured by patient scores on the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) questionnaire. The FACT-VCI is a condition-specific instrument for patients undergoing radical cystectomy (RC) and urinary diversion (UD) for bladder cancer. The questionnaire consists of 44 items scored on a range from 0 ("Not at all") to 4 ("Very Much"), resulting in an ordinal Likert scale, with higher scores indicating a better HRQoL. The FACT-VCI measures quality of life across five domains: Physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and an additional concerns subscale.

Trial Locations

Locations (1)

University of Miami; 🇺🇸 Miami, Florida, United States